Needham analyst Ami Fadia has reiterated the "Buy" rating for Revolution Medicines (RVMD, Financial), maintaining the company's price target at $57.00 USD. This decision reflects a steady outlook on the stock, as the analyst previously set the same price target.
The maintained price target indicates confidence in Revolution Medicines' (RVMD, Financial) market position and potential for growth. The analyst's consistent stance comes despite any market fluctuations, emphasizing the stock's stability.
As of June 24, 2025, the rating for Revolution Medicines (RVMD, Financial) remains "Buy," indicating that Needham sees potential upside and solid performance prospects for the company in the future.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Revolution Medicines Inc (RVMD, Financial) is $72.60 with a high estimate of $88.00 and a low estimate of $57.00. The average target implies an upside of 81.36% from the current price of $40.03. More detailed estimate data can be found on the Revolution Medicines Inc (RVMD) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Revolution Medicines Inc's (RVMD, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Revolution Medicines Inc (RVMD, Financial) in one year is $0.35, suggesting a downside of 99.13% from the current price of $40.03. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Revolution Medicines Inc (RVMD) Summary page.
